SeekingAlpha · Jan 11, 2026
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria - Slideshow
2026-01-11. The following slide deck was published by Jasper Therapeutics, Inc.
JS
NASDAQ · JSPRW
Japer Therapeutics, Inc. Warrants
Healthcare · Biotechnology
$0.00
Down-$0.00 (-84.62%)
Updated Oct 7, 2026, 11:37 AM
SID Score
2.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.03M
- P/E ratio
- -0.43
- Dividend yield
- 0.00%
- 52-week range
- $0.00 – $0.02
- Volume
- 863.07K
- Avg. volume
- 8.89K
Price performance · JSPRW
JSPRW price history
1M range · 12 trading sessions · Daily adjusted prices
Prices through Sep 24, 2026
JSPRW closed at $0.00 after 12 trading sessions, down 97.30% for the selected period.
- Last close
- $0.00
- Period change
- -97.30%
- Period low
- $0.00
- Period high
- $0.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 24, 2026 | $0.0013 | $0.0039 | $0.0001 | $0.0002 | 863.07K |
| Sep 23, 2026 | $0.003 | $0.003 | $0.0012 | $0.0013 | 533.51K |
| Sep 22, 2026 | $0.0044 | $0.0044 | $0.0026 | $0.003 | 155.76K |
| Sep 21, 2026 | $0.0036 | $0.0052 | $0.0032 | $0.0044 | 97.32K |
| Sep 18, 2026 | $0.0031 | $0.005 | $0.0031 | $0.005 | 26.76K |
| Sep 17, 2026 | $0.0031 | $0.005 | $0.0031 | $0.005 | 13.54K |
| Sep 16, 2026 | $0.0075 | $0.0075 | $0.003 | $0.0049 | 184.04K |
| Sep 15, 2026 | $0.0074 | $0.0074 | $0.0056 | $0.0073 | 44K |
| Sep 14, 2026 | $0.0079 | $0.008 | $0.0067 | $0.008 | 12.44K |
| Sep 11, 2026 | $0.0057 | $0.008 | $0.0057 | $0.008 | 22.69K |
| Sep 9, 2026 | $0.0092 | $0.0092 | $0.0057 | $0.0085 | 62.59K |
| Sep 8, 2026 | $0.0057 | $0.0074 | $0.0057 | $0.0074 | 1.15K |
Latest JSPRW news
The latest Smart Investors Daily articles mentioning JSPRW.
Stock researchCompany · Overview
Company
Market Activity
Research & News
JSPRW research
Overview
Company profile and research snapshot.
Company profile
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
SeekingAlpha · Jan 8, 2026
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria January 8, 2026 8:00 AM ESTCompany...
GlobeNewswire Inc. · Nov 10, 2025
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against Jasper Therapeutics alleging false and misleading statements about manufacturing controls, product prospects, and potential regulatory issues during the period of November 30, 2023 to July 3, 2025.
GlobeNewswire Inc. · Nov 3, 2025
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Jasper Therapeutics faces a class action lawsuit alleging securities fraud after revealing issues with a drug product lot that impacted clinical trial results, leading to study halts and significant stock price decline.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
